- Home
- LGCY vs VERU Comparison
LGCY vs VERU Comparison
Compare LGCY & VERU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- VERU
- Stock Information
- Founded
- LGCY 2009
- VERU 1971
- Country
- LGCY United States
- VERU United States
- Employees
- LGCY N/A
- VERU N/A
- Industry
- LGCY
- VERU Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- VERU Health Care
- Exchange
- LGCY NYSE
- VERU Nasdaq
- Market Cap
- LGCY 101.9M
- VERU 108.8M
- IPO Year
- LGCY 2024
- VERU 1990
- Fundamental
- Price
- LGCY $8.73
- VERU $0.98
- Analyst Decision
- LGCY Strong Buy
- VERU Strong Buy
- Analyst Count
- LGCY 2
- VERU 4
- Target Price
- LGCY $9.35
- VERU $4.00
- AVG Volume (30 Days)
- LGCY 100.1K
- VERU 2.2M
- Earning Date
- LGCY 11-14-2024
- VERU 02-06-2025
- Dividend Yield
- LGCY N/A
- VERU N/A
- EPS Growth
- LGCY 90.87
- VERU N/A
- EPS
- LGCY 0.63
- VERU N/A
- Revenue
- LGCY $49,638,473.00
- VERU $16,886,419.00
- Revenue This Year
- LGCY $32.23
- VERU N/A
- Revenue Next Year
- LGCY $20.60
- VERU N/A
- P/E Ratio
- LGCY $13.84
- VERU N/A
- Revenue Growth
- LGCY 32.36
- VERU 3.62
- 52 Week Low
- LGCY $3.60
- VERU $0.36
- 52 Week High
- LGCY $10.37
- VERU $1.92
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- VERU 74.65
- Support Level
- LGCY N/A
- VERU $0.70
- Resistance Level
- LGCY N/A
- VERU $0.81
- Average True Range (ATR)
- LGCY 0.00
- VERU 0.11
- MACD
- LGCY 0.00
- VERU 0.02
- Stochastic Oscillator
- LGCY 0.00
- VERU 95.26
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About VERU Veru Inc.
Veru Inc is a biopharmaceutical company with a drug development program for the treatment of metabolic diseases, oncology, and acute respiratory distress syndrome (ARDS). The company is also in the late-stage development of certain drugs for the management of breast and prostate cancers. It also has a sexual health program that includes two products, ENTADFI, for the treatment of benign prostatic hyperplasia (BPH) and the FC2 Female Condom (Internal Condom). The company operates in a single segment and generates revenue from the USA which is the key revenue generating market, Brazil, and other regions.